We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis (CLIPPER2)

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01421069
First Posted: August 22, 2011
Last Update Posted: November 9, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Pfizer
August 18, 2011
August 22, 2011
November 9, 2017
October 2011
March 2021   (Final data collection date for primary outcome measure)
Occurrence of malignancy [ Time Frame: up to 8 years ]
Same as current
Complete list of historical versions of study NCT01421069 on ClinicalTrials.gov Archive Site
  • Occurrence of withdrawals from investigational product [ Time Frame: up to 8 years ]
  • Physician's Global Assessment of Disease Activity on a 21-circle visual analogue scale [ Time Frame: up to 8 years ]
  • Patient/Parent Global Assessment on a 21-circle VAS [ Time Frame: up to 8 years ]
  • C-reative protein [ Time Frame: up to 8 years ]
  • Childhood Health Assessment Questionnaire (CHAQ) for subjects less than 18 years of age; Health Assessment Questionnaire (HAQ) for subjects greater than or equal to 18 years of age. [ Time Frame: up to 8 years ]
  • ACR Pediatric 30, 50, 70, 90, and 100 [ Time Frame: up to 8 years ]
  • Individual components of the ACR Pediatric Assessments [ Time Frame: up to 8 years ]
  • Pain Assessment on a 21-circle VAS [ Time Frame: up to 8 years ]
  • Duration of morning stiffness in minutes [ Time Frame: up to 8 years ]
  • Clinically inactive disease defined as follows per Wallace Criteria [ Time Frame: up to 8 years ]
  • The Juvenile Arthritis Disease Activity Score (JADAS) [ Time Frame: up to 8 years ]
  • Overall Back Pain and Nocturnal Back Pain on a 100 mm VAS (ERA subjects only) [ Time Frame: up to 8 years ]
  • Bath Ankylosing Spondylitis Metrology Index [ Time Frame: up to 8 years ]
  • Body Surface Area (PsA subjects only) [ Time Frame: up to 8 years ]
  • Physician Global Assessment of Psoriasis (PsA subjects only) [ Time Frame: up to 8 years ]
  • Occurrence of withdrawals from investigational product [ Time Frame: up to 8 years ]
  • Physician's Global Assessment of Disease Activity on a 21-circle visual analogue scale [ Time Frame: up to 8 years ]
  • Patient/Parent Global Assessment on a 21-circle VAS [ Time Frame: up to 8 years ]
  • C-reative protein [ Time Frame: up to 8 years ]
  • Childhood Health Assessment Questionnaire (CHAQ) for subjects less than 18 years of age; Health Assessment Questionnaire (HAQ) for subjects greater than or equal to 18 years of age. [ Time Frame: up to 8 years ]
Not Provided
Not Provided
 
Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis
An Open-label Extension Study To Assess The Long-term Safety And Clinical Benefit Of Etanercept In Children And Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-related Arthritis, Or Psoriatic Arthritis Who Were Previously Enrolled In Protocol 0881a1-3338-ww(b1801014)
This is a 8-year extension study in pediatric subjects who have been diagnosed with one of 3 subtypes of Juvenile Idiopathic Arthritis (JIA) [extended oligoarticular JIA, enthestitis related arthritis (ERA), or psoriatic arthritis (PsA)] who have completed approximately 96 weeks of participation in study 0881A1-3338 (B1801014). The study contains an active treatment period, withdrawal/re-treatment period and a observational period (non-treatment).
Not Provided
Interventional
Phase 3
Masking: None (Open Label)
Primary Purpose: Treatment
Juvenile Idiopahtic Arthritis
Drug: etanercept

Subjects aged <18 years and less than or equal to 62 kg will receive etanercept SC at a dose of 0.8 mg/kg QW (up to a maximum dose of 50 mg QW).

Subjects aged greater than or equal to 18 years or >62 kg will receive etanercept SC at a dose of 50 mg QW.

Experimental: 1
Intervention: Drug: etanercept
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
109
March 2021
March 2021   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Receipt of at least 1 dose of investigational product (etanercept) and participation for approximately 96 weeks in study 0881A1-3338 (B1801014)

Personally signed and dated informed consent document (and assent document, as applicable) indicating the subject (or legally representative/guardian) has been informed of all pertinent aspects of the study.

Exclusion Criteria:

Exclusion criteria for subject planning to continue investigational product:

withdrawal from investigational product in study 0881A1-3338 for any reason (safety or non-safety).

History of maliginancy other than squamous cell, basal cell carcinoma or cervical carcinoma in situ.

Sexes Eligible for Study: All
2 Years to 30 Years   (Child, Adult)
No
Contact information is only displayed when the study is recruiting subjects
Australia,   Belgium,   Colombia,   Czechia,   France,   Germany,   Hungary,   Italy,   Latvia,   Lithuania,   Mexico,   Netherlands,   Norway,   Poland,   Russian Federation,   Serbia,   Slovakia,   Slovenia,   Spain
Czech Republic
 
NCT01421069
B1801023
0881A1-3342 ( Other Identifier: Alias Study Number )
2010-023802-10 ( EudraCT Number )
Yes
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
November 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP